The popularity of Sildenafil initially drove a surge for pharma, but recent changes present a complicated outlook for investors. Off-patent versions are eating into revenue, and persistent litigation add additional https://livianzsi225404.blogzet.com/sildenafil-and-the-pharmaceutical-industry-a-volatile-bet-56233450